U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. ACRX Specialty Pharmacy Inc - 609518 - 07/13/2022
  1. Warning Letters

CLOSEOUT LETTER

ACRX Specialty Pharmacy Inc MARCS-CMS 609518 —

Delivery Method:
VIA EMAIL CONFIRMED DELIVERY
Product:
Drugs
Recipient:
Recipient Name
Eghomware J. Igbinovia
Recipient Title
Pharmacist-in-Charge/Owner
ACRX Specialty Pharmacy Inc

3200 Soaring Gulls Dr
STE 101
Las Vegas, NV 89129-2198
United States

jerry@acrxpharmacy.com
Issuing Office:
Center for Drug Evaluation and Research | CDER

United States

Dear Mr. Igbinovia:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [case #: 609518; dated July 24, 2020]. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

If there is any question, please contact LCDR Rumany Penn, compliance officer, at 949-608-4409, or by email at Rumany.Penn@fda.hhs.gov.

Sincerely,
/S/
CDR Steven E. Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV

Back to Top